Abbott's a Great Place to Work, According to Science

Abbott named a top employer by "Science," evaluated by 6,000 people in science fields around the world

For the 13th year, the journal Science today recognized Abbott (No. on the DiversityInc Top 50 Companies list) on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.


"Abbott is unique in that we've been adding to our reservoir of scientific knowledge for 128 years," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track. "We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people's lives."

The clarity of Abbott's mission to help people live better, fuller lives through the power of health creates an environment that fosters growth and development as a scientist, Frels said – and ultimately leads to our next great innovations.

"We place great importance on the patient – the person that our products are ultimately designed to help." Frels said. "And that appeals to the hearts and the minds of our scientists – they know that what they're doing is making a difference in people's lives."

ABBOTT WIDELY RECOGNIZED AS A GREAT PLACE TO WORK

Scientists at Abbott are given opportunities to advance science, technology, medicine and nutrition to help people live fuller and more complete lives. The company recognizes this commitment through a number of internal recognition efforts, including chairman's awards, president's awards, and patent and inventor awards. The company honors its most distinguished scientists and engineers with induction into the prestigious Volwiler Society, named for the lateErnest H. Volwiler, Ph.D., an internationally recognized scientist and former Abbott president and chairman of the board.

In addition to being honored for workplace leadership by Science, FORTUNE magazine has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983. Working Mother and DiversityInc magazines have also ranked Abbott as a top employer, and the National Association for Female Executives again named Abbott among the Top 50 Companies for Executive Women in 2016.

About the 2016 Science Survey:

Nearly 6,000 scientists from around the world (56 percent North America; 28 percent Europe; and 12 percent Asia/Pacific Rim) voted on the companies they considered the best, average and worst employers. Here's a complete list of the rankings, which are also available in the Oct. 28, 2016, print edition of Science.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.